Rheumatoid Arthritis (RA)
This rheumatoid arthritis (RA) algorithm was created using a machine-learning logistic regression model.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Laboratories
Rheumatology Auto-Immune characteristics
Dear,
To identify cases with auto-immune rheumatologic phenotye (for NT198) we request information about auto-antibody (whether it was tested and what the restults were) and drug information (whether it was prescribed) for each patients that is enrolled in eMERGE. We are requesting every mention of any of the expanded generic drugs.
Owner Phenotyping Groups:
Final
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria
Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Statins and MACE
Phenotype Description: Patients on statins for primary prevention who develop an AMI or 1st AMI.
Below are algorithms used to identify AMI and 1st AMI cohort at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:
Wei-Qi Wei at wei-qi.wei@vanderbilt.edu
Joshua Denny at josh.denny@vanderbilt.edu
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Systemic lupus erythematosus (SLE)
We used Vanderbilt’s Synthetic Derivative (SD), a de-identified version of the EHR, with 2.5 million subjects. We selected all individuals with at least one SLE ICD-9 code (710.0) yielding 5959 individuals. To create a training set, 200 were randomly selected for chart review. A subject was defined as a case if diagnosed with SLE by a rheumatologist, nephrologist, or dermatologist.
Final
Type 1 and type 2 Diabetes Mellitus
This document describes the Stanford University algorithm to extract individuals with diabetes and the type of diabetes from electronic health records (EHRs). There are two main tasks of this phenotype development: 1) to extract patients with diabetes (gestational diabetes is excluded), and 2) to discriminate between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Instead of identifying all diabetes cases, we aim to reduce the number of false positives in our diabetes cohort.
Final
Type 1 Diabetes
Phenotype Algorithm for Type 1 Diabetes – eMERGE Phase-IV Program
Owner Phenotyping Groups:
Final
Type 2 Diabetes - Demonstration Project
Type 2 Diabetes phenotype algorithm for the DNA Databank Demonstration Project.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Type 2 Diabetes Mellitus
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Type1 or Type 2 Diabetes Mellitus
Phenotyping algorithm for the identification of patients with type 1 or type 2 diabetes mellitus (DM) preoperatively using routinely available clinical data from electronic
health records.
View Phenotyping Groups:
Final